Nektar says Eli Lilly miscalculated data in eczema trial before breaking off rezpeg partnership
07 Aug 2023
Phase 1Clinical ResultPhase 2PROTACs
Nektar Therapeutics said its former partner Eli Lilly had presented “erroneous data” for its atopic dermatitis drug before breaking off a $400 million alliance.
Whereas the miscalculated Phase Ib data were enough for Nektar to move ahead with plans for a Phase IIb study, the biotech said the “new and corrected data” suggest its candidate, rezpegaldesleukin, had even better results on the Eczema Area and Severity Index (EASI). In particular, NektarNektar underscored that on the highest dose, rezpegaldesleukin spurred an 83% improvement on EASI at 12 weeks, with a p-value of 0.002 compared to placebo.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.